TEL: +86-21-50180596 Email: sales@biopharmaleader.com

Search

Contact Us

Tel: 0086 21 50180596

Fax: 0086 21 57758967

Mob: 0086 18721201413

E-mail:sales@biopharmaleader.com

Exhibition
Home > Exhibition > Content

Pfizer completes acquisition of Anacor Pharmaceuticals

Shanghai Biopharmaleader Co.,Ltd | Updated: Jun 28, 2016

Pfizer has completed its acquisition of Anacor Pharmaceuticals.

Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive $99.25 net in cash. The total transaction value is approximately $5.2 billion.

Commenting on the news, Albert Bourla, Group President, Pfizer Innovative Health, said: “Now that Anacor is part of Pfizer, we can accelerate our shared commitment to help patients with inflammatory disease, an area of high unmet medical need. We believe that Pfizer is in a position to quickly capitalize on the benefits offered by the combination with Anacor, including the potential for a near-term U.S. product launch and subsequent commercialization of crisaborole, a differentiated asset with compelling clinical data. If approved, crisaborole has the potential to be an important first-line treatment option for patients with mild-to-moderate atopic dermatitis and the physicians who treat them.”

Shanghai Biopharmaleader Co.,Ltd